Who Paid My Doc
Vivian Wang
Surgery Salt Lake City, UT Medical Doctor
NPI 1417392671 CMS profile 5975686
324 E 10Th Ave Ste 200, Salt Lake City, UT 84103
General payments
$26,254
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Vivian Wang of Salt Lake City, UT is reported in the CMS Open Payments database as having received $26,254 across 105 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $33 | 1 | |
| 2024 | General | $6,993 | 29 | |
| 2023 | General | $1,640 | 19 | |
| 2022 | General | $12,711 | 36 | |
| 2021 | General | $1,945 | 10 | |
| 2020 | General | $2,082 | 4 | |
| 2019 | General | $849 | 6 |
Beside peers
- Vivian Wang
- Surgery median
- Middle half of Surgery
- National median
In program year 2025, general payments to Vivian Wang were reported at $33. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.
Show as a table
| Year | Vivian Wang | Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $849 | $253 | $82–$1,521 | $163 |
| 2020 | $2,082 | $131 | $40–$706 | $114 |
| 2021 | $1,945 | $168 | $50–$904 | $132 |
| 2022 | $12,711 | $224 | $76–$1,218 | $149 |
| 2023 | $1,640 | $253 | $82–$1,255 | $160 |
| 2024 | $6,993 | $279 | $90–$1,381 | $164 |
| 2025 | $33 | $280 | $91–$1,259 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
116
Drug cost
$1,578
Branded share of claims
12.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ursodiol | Generic | 15 | $622 | |
| Pantoprazole Sodium | Generic | 46 | $488 | |
| Ondansetron Hcl | Generic | 19 | $173 | |
| Ondansetron Odt Ondansetron | Brand | 14 | $152 | |
| Oxycodone Hcl | Generic | 22 | $144 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$2,904
Medicare patients
13
Services billed
15
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
105 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgery in Utah
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.